A platform-level FDA view is emerging that GenAI-enabled medical tools may need evaluation “like a physician,” with algorithm behavior assessed for clinical trustworthiness rather than as passive software. The statement highlights an internal regulatory direction for digital health, implying higher scrutiny for how models make or justify decisions in high-stakes workflows.